487基因表达特征测试指导全身疗法选择,以改善阿托皮性皮肤炎患者的治疗结果:来自前性试验的结果
Jonathan I Silverberg1, Lawrence F Eichenfield2, April W Armstrong3
1Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, D.C.
Journal of the American Academy of Dermatology
|February 18, 2026
概括
一个新的基因表达特征 (GEP) 测试准确地预测了阿托皮性皮肤炎 (AD) 治疗反应. 这种487-GEP测试有助于识别可能受益于JAK抑制剂而不是Th2向治疗的患者.
科学领域:
- 皮肤病学 皮肤病学
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 目前的阿托皮性皮炎 (AD) 治疗选择缺乏个性化,导致许多患者的疾病控制不足.
- 在当前的治疗策略中,AD的分子驱动因素没有被考虑.
- 这突显了在AD治疗中需要精准医学方法的需要.
研究的目的:
- 开发和验证一种基因表达特征 (GEP) 测试,用于指导亚托皮炎的全身疗法选择.
- 目标是通过将患者与基于其分子形状的疗法相匹配来提高治疗效率.
主要方法:
- 一项前性研究分析了来自阿尔茨海默病和牛皮病患者皮肤痕的RNA测序数据.
- 使用12个神经网络和487个基因开发了一种集成算法,即487-GEP,用于预测治疗反应.
- 该算法对192名患者进行了训练,并对110名阿尔茨海默病患者进行了验证,评估了EASI,和爆发频率等结果.
主要成果:
- 由487-GEP确定为JAK抑制剂 (JAKi) - 响应因子的AD患者显示出明显更高的EASI-90响应率 (45.5%与8.3%) 和较快的改善,与接受Th2向治疗的人相比.
- 这些JAKi-Responder-Profile患者在接受JAK抑制剂治疗时,也报告了较少的和增加的无发作率.
- 具有Th2分子概况的患者在JAKi和Th2向疗法之间的EASI-90反应中没有显著差异.
结论:
- 487-GEP测试有效地识别了与Th2向治疗相比,更有可能对JAK抑制剂产生反应的亚托皮肤炎患者.
- 这种基因表达特征测试为AD个性化治疗选择提供了有前途的工具.
- 需要进一步验证,因为目前的研究仅限于12岁及以上的患者.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
01:11Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
01:16Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
01:29Pharmacogenomics: Identification of New Drug Targets
25
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25